[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Liapakis IE, Korkolis DP, Koutsoumbi A, Fida A, Kokkalis G, Vassilopoulos PP: Malignant hidradenoma: a report of two cases and review of the literature. Anticancer Res; 2006 May-Jun;26(3B):2217-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant hidradenoma: a report of two cases and review of the literature.
  • INTRODUCTION: Malignant tumors of the sweat glands are very rare.
  • Clear cell hidradenoma is a lesion with histopathological features resembling those of eccrine poroma and eccrine spiradenoma.
  • The biological behavior of the tumor is aggressive, with local recurrences reported in more than 50% of the surgically-treated cases.
  • MATERIALS AND METHODS: Two patients are presented, the first with tumor in the right axillary region, the second with a recurrent tumor of the abdominal wall.
  • Although he had received several chemotherapeutic agents, the disease had a relentless course and the patient succumbed two and a half years following surgery.
  • CONCLUSION: Malignant tumors of the sweat glands are very rare neoplasms with no discrete clinical characteristics.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821590.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, Hoang MP: Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol; 2010 Aug;32(6):586-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.
  • BACKGROUND: Epidermal growth factor receptor (EGFR) protein overexpression and gene amplification are important prognostic factors in various tumors and EGFR inhibitors are now available as promising chemotherapeutic agents.
  • There is little information in the literature regarding the EGFR protein and gene status in hidradenocarcinomas which has an aggressive biologic course characterized by repeated local recurrences and systemic metastasis.
  • We have previously reported EGFR protein overexpression in malignant, atypical, and benign hidradenomas and would like to further evaluate their gene status by fluorescence in situ hybridization.
  • METHODS: Fluorescence in situ hybridization by 2-color probe Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott Molecular) and EGFR immunostain (H11, Dakocytomation) were performed in 15 malignant, 15 atypical, and 7 benign hidradenomas.
  • Disomy is noted in the remaining 29 cases (9 hidradenocarcinomas, 15 atypical hidradenomas, and 5 benign hidradenomas).
  • EGFR overexpression was seen in 3/12 (25%) malignant hidradenomas, 7/15 (47%) atypical hidradenomas, and 3/5 (60%) benign hidradenomas; none of these cases demonstrated EGFR gene amplification.
  • CONCLUSIONS: Polysomy/trisomy is more frequently seen in hidradenocarcinoma than atypical and benign hidradenomas.
  • Lack of correlation between the protein expression and polysomy/gene amplification suggests that molecular mechanisms other than gene amplification play a role in EGFR overexpression in malignant, atypical, and benign hidradenomas.
  • [MeSH-major] Acrospiroma / pathology. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Proliferation. Chromosome Aberrations. Gene Amplification. Humans. In Situ Hybridization, Fluorescence / methods. Lymph Nodes / pathology. Trisomy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534988.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Al-Ahwal MS, Sawan AS, Zimmo SK: Malignant eccrine poroma. Saudi Med J; 2005 May;26(5):859-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign eccrine poroma arises from the intraepidermal portion of the eccrine gland duct.
  • We report a 44-year-old male patient who presented primarily with a lesion diagnostic of benign eccrine poroma of the right foot sole with no clear evidence of malignancy, which was incompletely excised, followed 5 months later by local recurrence, ulceration, occasional bleeding and right inguinal lymphadenopathy.
  • Incomplete excision of the primary tumor as well as excision of a skin lesion on the right knee joint revealed malignant eccrine poroma with aggressive histology, lymphovascular and perineural invasion.
  • This tumor might be malignant at the first presentation, which was not confirmed histopathologically considering the short duration of only 5 months for malignant transformation.
  • It has proven resistant to many chemotherapeutic agents and radiotherapy.
  • [MeSH-major] Foot Diseases / diagnosis. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Saudi Med J. 2005 Oct;26(10):1665; author reply 1665 [16228085.001]
  • (PMID = 15951884.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


Advertisement
4. Yildirim S, Aköz T, Akan M, Ege GA: De novo malignant eccrine spiradenoma with an interesting and unusual location. Dermatol Surg; 2001 Apr;27(4):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo malignant eccrine spiradenoma with an interesting and unusual location.
  • BACKGROUND: Reports in the literature reveal that malignant eccrine spiradenomas (MES) are exceedingly rare, and represent aggressive tumors arising in long-standing benign eccrine spiradenomas (ES).
  • OBJECTIVE: We present a de novo case of MES of the nose, in contrast to reports in the literature of progression from long-standing benign lesions.
  • RESULTS: Our case was accepted as de novo MES because there was no evidence of ES on pathologic examination.
  • It was treated by surgical excision with 1 cm tumor-free margins.
  • CONCLUSION: Although previously reported lesions have arisen in long-standing benign ESs, usually on the trunk or extremities, this report shows that MES may occur as a primary malignant tumor and may occur in unusual locations such as the nose.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Nose Neoplasms / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Colonic Neoplasms / secondary. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Malignant eccrine spiradenoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298720.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


5. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant; 2009 Feb;24(2):682-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA).
  • It was shown recently that sunitinib, a small molecule inhibiting several tyrosine kinase receptors, including VEGF receptors, can also induce proteinuria, hypertension and biological features of TMA. Case.
  • A 44-year-old woman with a history of malignant skin hidradenoma was started on sunitinib for refractory disease.
  • Renal function remained normal, and biological signs of TMA were absent.
  • This suggests that all anti-VEGF drugs may share a common risk for developing renal adverse events, including TMA.
  • The renin-angiotensin system blockers may be considered in patients with mild clinical manifestations and in the absence of therapeutic alternative to anti-VEGF drugs.
  • [MeSH-major] Indoles / adverse effects. Kidney / blood supply. Kidney / drug effects. Pyrroles / adverse effects. Thrombosis / chemically induced. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adenoma, Sweat Gland / drug therapy. Adult. Antineoplastic Agents / adverse effects. Female. Humans. Protein Kinase Inhibitors / adverse effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nephrol Dial Transplant. 2009 Jun;24(6):2002-3 [19332867.001]
  • (PMID = 19054798.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib
  •  go-up   go-down






Advertisement